Related Experiment Video
Updated: Aug 5, 2026
16:57
MALDI Imaging Mass Spectrometry of Neuropeptides in Parkinson's Disease
Published on: February 14, 2012
Selegiline for Parkinson's disease
1Hahnemann University School of Medicine, Philadelphia, Pennsylvania.
American Family Physician
|February 1, 1990
Summary
Selegiline, a selective monoamine oxidase inhibitor, effectively manages Parkinson's disease symptoms when combined with carbidopa/levodopa. This combination allows for reduced carbidopa/levodopa dosage, diminishing side effects and improving patient outcomes.
Area of Science:
- Neuroscience
- Pharmacology
- Clinical Medicine
Background:
- Nonselective monoamine oxidase inhibitors (MAOIs) affect both brain and peripheral MAO.
- Parkinson's disease management has historically relied on nonselective MAOIs.
Purpose of the Study:
- To evaluate the efficacy and safety of selegiline, a selective MAOI, in Parkinson's disease management.
- To assess the benefits of combining selegiline with carbidopa/levodopa.
Main Methods:
- Clinical trials were conducted to assess selegiline's effectiveness.
- Patient outcomes were monitored when selegiline was added to carbidopa/levodopa therapy.
Main Results:
- Selegiline in combination with carbidopa/levodopa effectively relieved Parkinson's disease symptoms.
- The combination therapy prolonged remission periods.
- Dosage reduction of carbidopa/levodopa was often possible, leading to fewer side effects.
- Selegiline demonstrated a relatively nontoxic profile.
Conclusions:
- Selegiline is a valuable therapeutic addition for Parkinson's disease.
- Selective MAOIs like selegiline offer an improved treatment option for Parkinson's disease patients.
- Combining selegiline with carbidopa/levodopa enhances symptom control and tolerability.
Related Concept Videos
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:24Parkinson Disease l: Introduction
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
01:11Alterations in Muscle Tone lll
Rigidity and myotonia are distinct abnormalities of muscle tone that affect resistance and relaxation during movement. Although both involve altered muscle contraction, they arise from different neurological and muscular mechanisms.CharacteristicsRigidity is characterized by uniform resistance to passive movement across the entire range, independent of speed, affecting flexors and extensors equally. It may appear as lead-pipe rigidity (smooth, constant resistance) or cogwheel rigidity...